SCHEMBL2581060

SCHEMBL2581060

CCc1cnc2c(c1)c(O)c(C(=O)NCC(=O)OC(C)(C)C)c(=O)n2C

nearest known ligand 0.42

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 3/20 0.42
HIF1A Q16665 14/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2586808 0.92 TSHR (0.41) EGLN1HIF1ATSHRMEN1NPC1
SCHEMBL12101566 0.91 L3MBTL1 (0.41) EGLN1HIF1ATSHRMEN1KMT2A
SCHEMBL12101565 0.88 EGLN1 (0.43) EGLN1HIF1ATSHRNPC1
SCHEMBL12171890 0.87 L3MBTL1 (0.39) EGLN1HIF1ATSHRMEN1NPC1
SCHEMBL2580158 0.87 HIF1A (0.41) EGLN1HIF1ATSHRMEN1NPC1
SCHEMBL2576293 0.87 EGLN1 (0.42) EGLN1HIF1ATSHR
SCHEMBL2581050 0.87 HIF1A (0.48) EGLN1HIF1AMEN1KMT2A
SCHEMBL12172186 0.87 EGLN1 (0.42) EGLN1HIF1ATSHR
SCHEMBL2582051 0.86 EGLN1 (0.54) EGLN1HIF1A
SCHEMBL2579371 0.84 EGLN1 (0.41) EGLN1HIF1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097416-B1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC (US) 2012-09-12 EP disclosed
EP-2097416-B1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC (US) 2012-09-12 EP disclosed
US-8048892-B2 Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-11-01 US disclosed
US-8048892-B2 Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-11-01 US disclosed
US-8048892-B2 Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-11-01 US disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 US disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 US disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 US disclosed
WO-2008076425-A1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof EGLN3, EGLN2, HIF1AN EGLN1 5/4885HIF1A 6/4885TSHR 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.